Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Clinical Cooperation Unit Applied Tumor Immunity

Prof. Dr. Dirk Jäger

Fundamental and translational research program of the CCU Applied Tumor Immunity for the development of novel cellular and antibody-based immunotherapeutic approaches. Created with BioRender.com.
© dkfz.de

The immune system influences the efficacy of many therapies and interventions. Thus, the identification of crucial immunological parameters, such as novel biomarkers, is of great importance. The aim of the Clinical Cooperation Unit (CCU) Applied Tumor Immunity is the characterization of immune responses directed against the tumor and the transfer of these findings into clinical applications. A particular focus of our research is the analysis of immunological interactions between tumor cells and host or immune cells in the tumor microenvironment and periphery to identify predictive biomarkers and develop novel immunotherapeutic approaches for solid tumors (e.g. TCR T cells, CAR T cells, bispecific antibodies and peptide vaccines).

In close collaboration with Prof. Jäger´s Department of Medical Oncology at the NCT Heidelberg and partners at the University Hospital (UKHD) and the Thoraxklinik Heidelberg we conduct innovative clinical trials and biomarker studies. Especially, the in-house development of cellular therapy approaches and various antibody formats, the clinical development of bispecific antibodies with pharmaceutical partners, and the application of organoid and tissue cultures as tumor model systems will lead to early clinical trials (phase I/II) evaluating novel (combination) therapies. The integration of research and clinic, in particular phase I/II clinical trials, is an explicit goal of our unit.

Research Groups within the Clinical Cooperation Unit Applied Tumor Immunity:

Contact

Prof. Dr. Dirk Jäger
Applied Tumor Immunity (D120)

German Cancer Research Center

National Center for Tumor Diseases (NCT) Heidelberg
Medical Oncology Department, Heidelberg University Hospital
Im Neuenheimer Feld 460
69120 Heidelberg
Phone: +49 6221 56 7228
E-Mail: dirk.jaeger@nct-heidelberg.de

Selected Publications

  • Warwas KM, Meyer M, Gonçalves M, Moldenhauer G, Bulbuc N, Knabe S, Luckner-Minden C, Ziegelmeier C, Heussel CP, Zörnig I, Jäger D, Momburg F. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models. Front Immunol 12:719116 (2021).
  • Rölle A, Meyer M, Calderazzo S, Jäger D, Momburg F. Distinct HLA-E Peptide Complexes Modify Antibody-Driven Effector Functions of Adaptive NK Cells. Cell Rep 24:1967-76.e4 (2018).
  • Bozza, M, De Roia A, Correia MP, Berger A, Tuch A, Schmidt A, Zörnig I, Jäger D, Schmidt P, Harbottle RP. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Science Advances, 7(16):eabf1333 (2021).
  • Quiros-Fernandez I, Poorebrahim M, Fakhr E, Cid-Arregui A. Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals. EBioMedicine 72:103610 (2021).
to top
powered by webEdition CMS